ADC Therapeutics (ADCT) Stock Statistics & Valuation Metrics

ADC Therapeutics has a market cap or net worth of $619.98M. The enterprise value is $782.19M.

ADC Therapeutics has 123,877,110 shares outstanding. The number of shares has decreased by -2.65% in one year.

ADC Therapeutics’s return on equity (ROE) is 0.77 and return on invested capital (ROIC) is -42.29%.

The current PE Ratio of ADC Therapeutics is ―. ADC Therapeutics’s PEG ratio is 0.10.

In the last 12 months, ADC Therapeutics had revenue of 73.55M and earned -142.62M in profits. Earnings per share was -1.12.

In the last 12 months, operating cash flow was -141.17M and capital expenditures -277.77K, giving a free cash flow of -141.45M billion.

ADC Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

ADC Therapeutics upcoming earnings date is May 11, 2026, Before Open (Confirmed).

ADC Therapeutics as a current ratio of 4.37, with Debt / Equity ratio of -236.24%

In the past 12 months, ADC Therapeutics has paid -1.01M in taxes.

ADC Therapeutics EV to EBITDA ratio is -5.15, with an EV/FCF ratio of -4.43.

ADC Therapeutics has $261.34M in cash and marketable securities with $439.01M in debt, giving a net cash position of -$177.67M billion.

Gross margin is 92.12%, with operating margin of -133.21%, and net profit margin of -175.31%.

The average price target for ADC Therapeutics is $8.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy